In Vitro and In Vivo Activities of DS-2969b, a Novel GyrB Inhibitor, against Clostridium difficile

DS-2969b is a novel GyrB inhibitor that is currently under clinical development for the treatment of Clostridium difficile infection (CDI). In this study, the in vitro and in vivo activities of DS-2969b were evaluated. DS-2969b inhibited the supercoiling activity of C. difficile DNA gyrase. DS-2969b...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Antimicrob Agents Chemother
Hlavní autoři: Mathur, Tarun, Barman, Tarani Kanta, Kumar, Manoj, Singh, Diksha, Kumar, Ram, Khera, Manoj Kumar, Yamada, Makiko, Inoue, Shin-ichi, Upadhyay, Dilip Jatashankar, Masuda, Nobuhisa
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society for Microbiology 2018
Témata:
Experimental Therapeutics
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5913969/
https://ncbi.nlm.nih.gov/pubmed/29439962
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.02157-17
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky